Global Cord Blood (CO) Competitors $0.75 0.00 (0.00%) As of 07/11/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CO vs. CORBF, MRAI, REPL, VIR, MPLN, SION, GYRE, OMI, CBLL, and NUTXShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Global Cord Blood (CORBF), Marpai (MRAI), Replimune Group (REPL), Vir Biotechnology (VIR), MultiPlan (MPLN), Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Owens & Minor (OMI), CeriBell (CBLL), and Nutex Health (NUTX). Global Cord Blood vs. Its Competitors Global Cord Blood Marpai Replimune Group Vir Biotechnology MultiPlan Sionna Therapeutics Gyre Therapeutics Owens & Minor CeriBell Nutex Health Global Cord Blood (NYSE:CO) and Global Cord Blood (NYSE:CORBF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media favor CO or CORBF? In the previous week, Global Cord Blood had 2 more articles in the media than Global Cord Blood. MarketBeat recorded 2 mentions for Global Cord Blood and 0 mentions for Global Cord Blood. Global Cord Blood's average media sentiment score of 0.12 beat Global Cord Blood's score of 0.00 indicating that Global Cord Blood is being referred to more favorably in the media. Company Overall Sentiment Global Cord Blood Neutral Global Cord Blood Neutral Is CO or CORBF more profitable? Company Net Margins Return on Equity Return on Assets Global Cord BloodN/A N/A N/A Global Cord Blood N/A N/A N/A Which has more volatility and risk, CO or CORBF? Global Cord Blood has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500. Which has better earnings & valuation, CO or CORBF? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Cord Blood$1.24B0.07$79.04M$0.641.17Global Cord Blood$196.12M0.46$79.04MN/AN/A SummaryGlobal Cord Blood beats Global Cord Blood on 4 of the 5 factors compared between the two stocks. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CO vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$91.16M$68.49M$5.56B$20.65BDividend YieldN/AN/A5.06%3.72%P/E Ratio1.170.5928.2327.84Price / Sales0.070.40434.2042.37Price / Cash4.192.8037.1222.32Price / Book0.120.128.044.57Net Income$79.04M$43.11M$3.19B$989.30M7 Day PerformanceN/A-30.95%3.62%0.20%1 Month Performance-28.57%-18.81%5.98%5.53%1 Year Performance-37.50%3.89%29.39%10.30% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGlobal Cord BloodN/A$0.75flatN/AN/A$91.16M$1.24B1.171,202News CoverageCORBFGlobal Cord BloodN/A$1.50flatN/AN/A$182.33M$196.12M0.001,200MRAIMarpaiN/A$1.35-6.9%N/A+86.7%$22.32M$34.87M-0.51150Gap DownREPLReplimune Group4.0717 of 5 stars$9.29-0.4%$20.83+124.3%+5.9%$719.22MN/A-3.03210News CoverageVIRVir Biotechnology3.6067 of 5 stars$5.04-2.5%$32.86+551.9%-39.7%$714.69M$74.21M-1.19580News CoverageAnalyst UpgradeMPLNMultiPlan0.17 of 5 stars$43.58+1.9%$26.25-39.8%N/A$704.73M$930.62M-0.46170News CoverageHigh Trading VolumeSIONSionna TherapeuticsN/A$17.35+9.5%$38.50+121.9%N/A$698.92MN/A0.0035News CoverageGYREGyre Therapeutics0.2336 of 5 stars$7.35-0.9%N/A-44.2%$695.68M$105.76M367.6840Positive NewsOMIOwens & Minor4.6607 of 5 stars$9.10+2.6%$11.60+27.5%-40.9%$685.25M$10.70B-1.9223,200News CoverageCBLLCeriBell2.5951 of 5 stars$18.73-0.9%$32.14+71.6%N/A$683.10M$65.44M0.00N/ANews CoverageInsider TradeNUTXNutex Health2.6386 of 5 stars$124.49+1.3%$262.50+110.9%+2,169.5%$682.72M$479.95M10.471,150High Trading Volume Related Companies and Tools Related Companies CORBF Competitors MRAI Competitors REPL Competitors VIR Competitors MPLN Competitors SION Competitors GYRE Competitors OMI Competitors CBLL Competitors NUTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CO) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
